Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z. +16 more·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1607751

Cited by (1,433)

Items 701–800 of 1,433

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Marc Justin Braunstein, Jonathan Weltz, Faith E. Davies · 2021 · Expert Review of Hematology
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Andrzej J. Jakubowiak, Saad Z. Usmani, Amrita Y. Krishnan, Sagar Lonial, Raymond L. Comenzo, Jianping Wang, Carla de Boer, William M Deraedt, Brendan M. Weiss, Jordan Mark Schecter et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications
Jaqueline Schütt, Theresa Maria Nägler, Tino Schenk, Annamaria Brioli · 2021 · Cancers
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik Hellem Schjesvold, Ivan Špıčka, Vladimír Maisnar, Artur J. Jurczyszyn, Zhanet G. Grudeva-Popova, Roman Hájek, Ganna Usenko et al. · 2023 · Haematologica
Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database
Junlin Wu, Han-Biao Wu, Lili Chen, Haiping Liang, Guoning Huang, Sensen Yang, Bishan Chen, Yoshihiro Noguchi, Yonggang Shen · 2023 · Expert Opinion on Drug Safety
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
Korean Multiple Myeloma 151 Investigators, Junghoon Shin, Je‐Jung Lee, Kihyun Kım, Chang‐Ki Min, Jeong‐Ok Lee, Cheolwon Suh, Jin Seok Kim, Yoo Jin Lee, Sung‐Soo Yoon et al. · 2018 · International Journal of Hematology
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
Massimo Offidani, Mario Boccadoro, Francesco Di Raimondo, Maria Teresa Petrucci, Patrizia Tosi, Michèle Cavo · 2019 · Current Hematologic Malignancy Reports
Moving Toward Continuous Therapy in Multiple Myeloma
Francesca Bonello, Giusy Cetani, Luca Bertamini, Francesca Gay, Alessandra Larocca · 2019 · Clinical Hematology International
Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
Sahar Khan, Alon Vaisman, Susy S. Hota · 2019 · JAMA Oncology
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, Sagar Lonial, Andrzej J. Jakubowiak, Albert Oriol, Amrita Y. Krishnan, Joan Bladé, Man Luo, Yu‐Nien Sun et al. · 2020 · Advances in Therapy
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
Xiaoyu Yan, Xu Steven Xu, Katja Christina Weisel, María‐Victoria Mateos, Pieter Sonneveld, Meletios Athanasios Dimopoulos, Saad Z. Usmani, Nizar Jacques Bahlis, Thomas A. Puchalski, Jon Ukropec et al. · 2020 · Clinical and Translational Science
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, Noriko Fukuhara, Sachiko Seo, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura et al. · 2020 · British Journal of Haematology
Antibody-Based Treatment Approaches in Multiple Myeloma
Hitomi Hosoya, Surbhi Sidana · 2021 · Current Hematologic Malignancy Reports
Drug resistance and minimal residual disease in multiple myeloma
Alessandro Gozzetti, Sara Ciofini, Anna Sicuranza, Paola Pacelli, Donatella Raspadori, Emanuele Cencini, Dania Tocci, Monica Bocchia · 2022 · Cancer Drug Resistance
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
Sebastian Böttcher · 2019 · Methods in molecular biology
Daratumumab–bortezomib–dexamethasone use in relapsed POEMS syndrome
Jahanzaib Khwaja, Ryan Yann Shern Keh, Duncan Smyth · 2022 · eJHaem
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Kimberly Ann Noonan, Kathleen Colson · 2017 · Seminars in Oncology Nursing
Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico
Jorge Vela‐Ojeda, David Gómez‐Almaguer, Ramiro Espinoza-Zamora et al. · 2021 · Archives of Medical Research
Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma
Katharine S. Gries, John M. Fastenau, Caroline Seo, Barbara Potrata, Charles Iaconangelo, Daniel Serrano · 2021 · Value in Health
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma
Margaux Lejeune, Murat Cem Köse, Mégane Jassin, Marie‐Jia Gou, Amaury Herbet, Elodie Duray, Gaël Cobraiville, Jacques Foguenne, Didier Boquet, André Gothot et al. · 2023 · HemaSphere
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel et al. · 2024 · Advanced Science
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
Peter H. Langer, Lukas John, Ina Monsef · 2024 · Cochrane Database of Systematic Reviews
How is patient care for multiple myeloma advancing?
Sonja Genadieva Stavric, Francesca Bonello, Sara Bringhen, Mario Boccadoro, Alessandra Larocca · 2017 · Expert Review of Hematology
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis
Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Teng-Fei Lin, Tiantian Zhang, Jie Jiang · 2019 · Clinical Lymphoma Myeloma & Leukemia
Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
Laurent Garderet, Curly Morris, Meral Beksaç, Gösta Gahrton, Stefan Olaf Schönland, Ibrahim Yakoub‐Agha, Patrick John Hayden · 2020 · Transplantation and Cellular Therapy
Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review
Salimah Valliani, Mir Jafer Ali, Omar Mahmood · 2020 · Case Reports in Hematology
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial
Evangelos Terpos, Meletios Athanasios Dimopoulos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Alessandra Pompa, Argiris S. Symeonidis, Jelena Bila et al. · 2022 · American Journal of Hematology
Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma
Shuchan Li, Gaofeng Zheng, Jingsong He, Wenjun Wu, Qingxiao Chen, Yang Yang, Donghua He, Yi Zhao, Xiaoyan Han, Zhen Cai · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Martin Štork, Ivan Špıčka, Jakub Radocha, Jiří Minařík, Tomáš Jelı́nek, Alexandra Jungová, Petr Pavlíček, Lenka Pospíšilová, František Sedlák, Jan Štraub et al. · 2023 · Annals of Hematology
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase
Sarah A. Holstein, Jens Hillengaß, Philip L. McCarthy · 2018 · Journal of Clinical Oncology
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A. Holstein, J Christine Ye, Alan Howard, Manisha Bhutani, Nicole J. Gormley, Theresa Hahn, Jens Hillengaß, Amrita Y. Krishnan, Ola Landgren, Nikhil C. Munshi et al. · 2018 · Transplantation and Cellular Therapy
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi‐centre cohort study
Chhay Lim, Priyadarshini Sinha, Simon James Harrison · 2020 · Mycoses
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Kathryn T. Maples, Nisha S. Joseph, Robert Donald Harvey · 2020 · Expert Review of Anticancer Therapy
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
Xiaorui Li, Yaru Feng, Fengqin Shang · 2021 · Frontiers in Oncology
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma
Lauren Westfall Veltri, Denái R. Milton, Ruby Delgado, Nina D. Shah, Krina K. Patel, Yago L. Nieto, Partow Kebriaei, Uday Popat, Simrit Parmar, Betül Oran et al. · 2017 · Cancer
Why Immunotherapy Fails in Multiple Myeloma
Luis Gerardo Rodríguez‐Lobato, Aina Oliver‐Caldés, David Fernando Moreno, Carlos Fernández de Larrea, Joan Bladé · 2020 · Hemato
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia
Esperanza Martín‐Sánchez, Laura Blanco, Peter Kim et al. · 2024 · Blood Advances
A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies
Aintzane Zabaleta, Laura Blanco, Peter S. Kim, Kamlesh Kumar Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis‐Esteban Tamariz‐Amador, Paula Rodríguez‐Otero, Jesús F. San Miguel et al. · 2024 · British Journal of Haematology
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Andrew Jenho Yee, Jacob P. Laubach, Erica Leigh Campagnaro, Brea C. Lipe, Omar Nadeem, Robb S. Friedman, Craig Emmitt Cole, Elizabeth O’Donnell, Giada Bianchi, Andrew Robert Branagan et al. · 2024 · Blood Advances
Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration Adverse Event Reporting System
Yuhao Zhong, Wei Dai, Lin Yin · 2025 · JBMR Plus
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Sung‐Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joonho Moon, Chang‐Ki Min, Dok Hyun Yoon, Sung Soo Yoon, Je‐Jung Lee, Chae Moon Hong et al. · 2025 · Blood Research
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis
Man Luo, Peijuan Zhu, Ivo P. Nnane, Yuan Xiong, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh D. Wechalekar, Brendan M. Weiss, NamPhuong Tran et al. · 2021 · The Journal of Clinical Pharmacology
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi et al. · 2021 · European Journal Of Haematology
Daratumumab Utilization and Cost Analysis among Patients with Multiple Myeloma in a US Community Oncology Setting
Lucio Gordan, Stanley M. Marks, Mei Xue · 2021 · Future Oncology
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma
Nathalie Roders, Cécilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Caroline Choisy, Elisabeth Nelson, Claire Maillard, David Garrick, Alexis Talbot et al. · 2024 · Cancer Immunology Research
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt · 2018 · Critical Reviews in Oncology/Hematology
Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy
Manon Bosseler, Vanessa Marani, Angelina Broukou, Amandine Lequeux, Tony Kaoma, Vincent Schlesser, Jean-Hugues François, Valérie Palissot, Guy Berchem, Nasséra Aouali et al. · 2018 · International Journal of Molecular Sciences
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
Hind Rafei, Faysal Haroun, Imad A. Tabbara · 2018 · American Journal of Clinical Oncology
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
M Campioni, Ion Agirrezabal, Roman Hájek, Jiří Minařík, Luděk Pour, I. Spicka, Sebastian Gonzalez‐McQuire, Petra Jandová, Vladimír Maisnar · 2019 · The European Journal of Health Economics
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu, Shinsuke Iida, Hirohiko Shibayama, Kazuhiro Shibayama, Hiroshi Yamazaki, Kenshi Suzuki · 2020 · International Journal of Hematology
Immunotherapy in multiple myeloma: when, where, and for who?
Christie P.M. Verkleij, Charlotte L.B.M. Korst, Niels W.C.J. van de Donk · 2020 · Current Opinion in Oncology
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Shambavi Richard, Sundar Jagannath, Hearn Jay Cho, Samir Sunil Parekh, Deepu Madduri, Joshua Ryan Richter, Ajai Chari · 2020 · Expert Review of Hematology
What Is New in the Treatment of Smoldering Multiple Myeloma?
Niccolò Bolli, Nicola Sgherza, Paola Curci, Rita Rizzi, Vanda Strafella, Mario Delia, Vito Pier Gagliardi, Antonino Neri, Luca Baldini, Francesco Albano et al. · 2021 · Journal of Clinical Medicine
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches
Juan José Lahuerta, Bruno Paiva, Ana Jiménez Ubieto, José M. Sánchez-Pina, María‐Victoria Mateos, Joan Bladé, Jesús F. San Miguel · 2021 · Blood Advances
Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States
Megan S. Rice, Sarah Naeger, Erin Singh · 2021 · Oncology and Therapy
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Xin Yi Wong, Wee Joo Chng, Mohamed Ismail Abdul Aziz, Kwong Ng · 2021 · Expert Review of Pharmacoeconomics & Outcomes Research
Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists
Catarina Geraldes, Manuel L Neves, Sergio Pereira Chacim, Fernando Leal da Costa · 2022 · Frontiers in Oncology
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Hira S. Mian, Christine Eisfeld, Christopher Paul Venner et al. · 2022 · Frontiers in Oncology
Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
Xavier P Leleu, Eirini Katodritou, Thomas Kuehr · 2022 · eJHaem
Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
Samuel Sherng Young Wang, Wee Joo Chng, Haiyan Liu, Sanjay De Mel · 2022 · Cancers
Safety issues and management of toxicities associated with new treatments for multiple myeloma
Annamaria Brioli, Lars‐Olof Mügge, Andreas Hochhaus, Marie von Lilienfeld‐Toal · 2017 · Expert Review of Hematology
Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
Tomoaki Fujisaki, Takayuki Ishikawa, Hiroyuki Takamatsu, Kenshi Suzuki, Chang‐Ki Min, Jae Hoon Lee, Jianping Wang, Robin L. Carson, Wendy A. Crist, Ming Qi et al. · 2019 · Annals of Hematology
Multiple myeloma: Current and future management in the aging population
Despina Fotiou, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Meletios Athanasios Dimopoulos · 2020 · Maturitas
How I Manage Frontline Transplant-Ineligible Multiple Myeloma
Daniele Derudas, Francesca Capraro, Giovanni Martinelli, Claudio Cerchione · 2020 · Hematology Reports
Promise of Immune Therapies in Multiple Myeloma
Kenneth Carl Anderson · 2018 · Journal of Oncology Practice
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Lisa K. Hicks, Hans J. Messersmith, Samer S.A. Al Hadidi, Rahul Kumar Banerjee, Benjamin Avi Derman, Shaji Kunnathu Kumar, Tanya Marya Wildes, Susan Bal, Sita Bhella, Cynthia Chmielewski et al. · 2026 · Journal of Clinical Oncology
Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity
Wei Liu, Juntao Yu, Kaiwen Sun, Qin Song, Yuling Li, Yanyun He, Yanrong Wang, Gang Xu, Changyu Wang, Bo Chen · 2024 · Frontiers in Immunology
Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials
Rana Jreich, Hao Zhang, Zhaoling Meng, Fei Wang · 2024 · Journal of Comparative Effectiveness Research
Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
Hua Jiang, Lu Li, Meiyu Guo, Meizhang Li, Hao Wu, Xiaomei Chen, Mingzhao Gao, Qianqian Xu, Jia Dai Mi, Canchan Cui et al. · 2024 · Hematology
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Paul Gerard Guy Richardson, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Fredrik Hellem Schjesvold, Monica Galli, Münci Yağcı, Alessandra Larocca, Katja Christina Weisel, Xin Yu et al. · 2025 · European Journal Of Haematology
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach
Aarthi Kannan, K. Jeffrey, Siraj Misbah, Karthik Ramasamy · 2025 · Blood Reviews
Fresh perspectives on treatment and moments of clarity
Prashant Kapoor, S. Vincent Rajkumar · 2017 · Nature Reviews Clinical Oncology
Multiple myeloma – 2020 update on diagnosis and management
Grzegorz Charliński, Artur J. Jurczyszyn · 2020 · Nowotwory Journal of Oncology
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
Dario Roccatello, Roberta Fenoglio, Carla Naretto · 2020 · Journal of Clinical Medicine
Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
Yaohua Cao, Lina Zhao, Tiantian Zhang, Weiling Cao · 2021 · Frontiers in Pharmacology
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
Hanyi Ding, Xiaoyuan Zhang, Dongxu Gang, Xiaoyu He, Songfu Jiang · 2022 · Translational Cancer Research
Multiple Myeloma: Possible Cure from the Sea
Anita Capalbo, Chiara Lauritano · 2022 · Cancers
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, Kenichi Miyamoto, Dai Maruyama, Kazuhito Yamamoto, Yoshifusa Takatsuka, Shigeru Kusumoto, Junya Kuroda, Kiyoshi Ando et al. · 2018 · Cancer Science
Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study
Robert M. Rifkin, David Singer, Kathleen M. Aguilar, Bismark Baidoo, Eric M. Maiese · 2019 · Clinical Therapeutics
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Benjamin T. Diamond, Kylee H. Maclachlan, David J. Chung, Alexander M. Lesokhin, Ola Landgren · 2020 · Best Practice & Research Clinical Haematology
ImmunoPET in Multiple Myeloma—What? So What? Now What?
Clément Bailly, Benjamin Chalopin, Sébastien Gouard, Thomas Carlier, Patricia Le Saëc, Séverine Marionneau‐Lambot, Philippe Moreau, Cyrille Touzeau, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin et al. · 2020 · Cancers
Daratumumab subcutaneous formulation for the treatment of multiple myeloma
Barry A. Paul, Issam S. Hamadeh, Shebli Atrash, Manisha Bhutani, Peter Michael Voorhees, Saad Z. Usmani · 2020 · Expert Opinion on Biological Therapy
Monoclonal antibodies as an addition to current myeloma therapy strategies
Maxime Jullien, Cyrille Touzeau, Philippe Moreau · 2020 · Expert Review of Anticancer Therapy
Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting
Nathan Andrew Rohner, Linda N. Purdue, Horst A. von Recum · 2020 · Journal of Pharmaceutical Sciences
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Sonia Morè, Maria Teresa Petrucci, Laura Corvatta, Francesca Fazio, Massimo Offidani, Attilio Olivieri · 2020 · Pharmaceuticals
New regimens and directions in the management of newly diagnosed multiple myeloma
Susan Bal, Smith Giri, Kelly Nicole Godby, Luciano J. Costa · 2021 · American Journal of Hematology
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
Gordon Cook, Alessandro Corso, Matthew J. Streetly, Larisa Pavlovna Mendeleeva, Vadim V. Ptushkin, Edmond S. Chan, Jon Ukropec, Wafae Iraqi, Assem Al-Akabawi, Huiling Pei et al. · 2021 · Oncology and Therapy
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Claudio Cerchione, Davide Nappi, Giovanni Martinelli · 2021 · Supportive Care in Cancer
Minimal Residual Disease in Multiple Myeloma
Roberto Mina, Francesca Bonello, Stefania Oliva · 2021 · The Cancer Journal
Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?
Oronza Antonietta Botrugno, Giovanni Tonon · 2021 · Cancers
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
Meletios Athanasios Dimopoulos, Joseph R Mikhael, Evangelos Terpos, Xavier P Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith E Stockerl-Goldstein, Paul Gerard Guy Richardson · 2022 · Therapeutic Advances in Hematology
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
Berenson, James R., Kim, Clara, Bujarski, Sean, To, Jennifer, Spektor, Tanya M., Martinez, Daisy, Turner, Carley, Ghermezi, Matthew, Eades, Benjamin M., Swift, Regina A. et al. · 2022 · Hematological Oncology
Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule
Beatrice Sim, Jun Yen Ng, Benjamin W. Teh · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
Ji Hyun Lee, Sung‐Hyun Kim, Hye Ryeon Kim, Chang‐Ki Min, Je‐Jung Lee, Ho‐Jin Shin, Jae‐Cheol Jo, Ji Yun Lee, Joon Ho Moon, Kihyun Kım · 2022 · International Journal of Hematology
Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways
Mehrdad Hashemi, Sophie Mousavian Roshanzamir, Mahshid Deldar Abad Paskeh, Seyedeh Sara Karimian, Mahdiyeh Sadat Mahdavi, Simin Khorsand Kheirabad, Sahar Naeemi, Afshin Taheriazam, Shokooh Salimimoghadam, Maliheh Entezari et al. · 2023 · European Journal of Pharmacology
Should minimal residual disease negativity be the end point of myeloma therapy?
Kenneth Carl Anderson · 2017 · Blood Advances
Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach
Verónica González‐Calle, Niamh Keane, Esteban Braggio, Rafaël Fonseca · 2017 · Clinical Lymphoma Myeloma & Leukemia
Antibody therapies for multiple myeloma
Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Evangelos Terpos · 2020 · Expert Opinion on Biological Therapy
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
Kenshi Suzuki · 2020 · International Journal of Hematology
Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review
Masaaki� Hotta, Tomoki� Ito, Akiko� Konishi, Hideaki� Yoshimura, Takahisa� Nakanishi, Shinya� Fujita, Atsushi� Satake, Shosaku� Nomura · 2021 · Internal Medicine